{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:23Z","timestamp":1786982783559,"version":"build-2736575974"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848101011"],"award-info":[{"award-number":["848101011"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101080009"],"award-info":[{"award-number":["101080009"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40273-025-01470-7","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T20:45:19Z","timestamp":1738961119000},"page":"483-497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in Oncology"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2201-5794","authenticated-orcid":false,"given":"Astrid","family":"Kramer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas F.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"van den Broek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit A.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1aki","family":"Gutierrez Ibarluzea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorea","family":"Galnares Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remond J. A.","family":"Fijneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolijn J. L.","family":"Ligtenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Schuuring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim H.","family":"van Harten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle M. H.","family":"Coup\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valesca P.","family":"Ret\u00e8l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the COIN Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"issue":"2","key":"1470_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jmoldx.2017.11.004","volume":"20","author":"NI Lindeman","year":"2018","unstructured":"Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018;20(2):129\u201359.","journal-title":"J Mol Diagn"},{"issue":"2","key":"1470_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41416-022-02017-9","volume":"128","author":"LG Faulkner","year":"2023","unstructured":"Faulkner LG, Howells LM, Pepper C, Shaw JA, Thomas AL. The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis. Br J Cancer. 2023;128(2):297\u2013309.","journal-title":"Br J Cancer"},{"issue":"4","key":"1470_CR3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1081\/CNV-58878","volume":"23","author":"MJ Goldstein","year":"2005","unstructured":"Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005;23(4):338\u201351.","journal-title":"Cancer Invest"},{"issue":"12","key":"1470_CR4","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1373\/clinchem.2012.182576","volume":"58","author":"PM Bossuyt","year":"2012","unstructured":"Bossuyt PM, Reitsma JB, Linnet K, Moons KG. Beyond diagnostic accuracy: the clinical utility of diagnostic tests. Clin Chem. 2012;58(12):1636\u201343.","journal-title":"Clin Chem"},{"issue":"3","key":"1470_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1177\/0272989X12452341","volume":"33","author":"T Merlin","year":"2013","unstructured":"Merlin T, Farah C, Schubert C, Mitchell A, Hiller JE, Ryan P. Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies. Med Decis Mak. 2013;33(3):333\u201342.","journal-title":"Med Decis Mak"},{"issue":"10","key":"1470_CR6","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.110.943860","volume":"123","author":"MJ Pletcher","year":"2011","unstructured":"Pletcher MJ, Pignone M. Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact. Circulation. 2011;123(10):1116\u201324.","journal-title":"Circulation"},{"issue":"1","key":"1470_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12874-021-01293-y","volume":"21","author":"A Hot","year":"2021","unstructured":"Hot A, Bossuyt PM, Gerke O, Wahl S, Vach W, Zapf A. Randomized test-treatment studies with an outlook on adaptive designs. BMC Med Res Methodol. 2021;21(1):110.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"1470_CR8","first-page":"1","volume":"5","author":"D Horgan","year":"2020","unstructured":"Horgan D, Ciliberto G, Conte P, Baldwin D, Seijo L, Montuenga LM, et al. Bringing greater accuracy to Europe\u2019s Healthcare Systems: the unexploited potential of biomarker testing in oncology. Biomed Hub. 2020;5(3):1\u201342.","journal-title":"Biomed Hub."},{"issue":"7","key":"1470_CR9","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40273-021-01010-z","volume":"39","author":"H Vellekoop","year":"2021","unstructured":"Vellekoop H, Huygens S, Versteegh M, Szilberhorn L, Zelei T, Nagy B, et al. Guidance for the harmonisation and improvement of economic evaluations of personalised medicine. Pharmacoeconomics. 2021;39(7):771\u201388.","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"1470_CR10","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1177\/0272989X18797590","volume":"38","author":"MM Kip","year":"2018","unstructured":"Kip MM, IJzerman MJ, Henriksson M, Merlin T, Weinstein MC, Phelps CE, et al. Toward alignment in the reporting of economic evaluations of diagnostic tests and biomarkers: the AGREEDT checklist. Med Decis Mak. 2018;38(7):778\u201388.","journal-title":"Med Decis Mak"},{"key":"1470_CR11","doi-asserted-by":"crossref","unstructured":"Shinkins B, Allen AJ, Karichu J, Garrison LP, Monz BU. Evidence synthesis and linkage for modelling the cost-effectiveness of diagnostic tests: preliminary good practice recommendations. Appl Health Econ Health Policy. 2024;22(2):131\u201344.","DOI":"10.1007\/s40258-023-00855-z"},{"issue":"6","key":"1470_CR12","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jval.2013.06.008","volume":"16","author":"L Annemans","year":"2013","unstructured":"Annemans L, Redekop K, Payne K. Current methodological issues in the economic assessment of personalized medicine. Value Health. 2013;16(6):S20\u20136.","journal-title":"Value Health."},{"issue":"1","key":"1470_CR13","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462322000484","volume":"38","author":"J Bouttell","year":"2022","unstructured":"Bouttell J, Heggie R, Oien K, Romaniuk A, VanSteenhouse H, von Delft S, Hawkins N. Economic evaluation of genomic\/genetic tests: a review and future directions. Int J Technol Assess Health Care. 2022;38(1): e67.","journal-title":"Int J Technol Assess Health Care"},{"issue":"sup245","key":"1470_CR14","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1080\/00365513.2016.1206437","volume":"76","author":"B Doble","year":"2016","unstructured":"Doble B. Budget impact and cost-effectiveness: can we afford precision medicine in oncology? Scand J Clin Lab Invest. 2016;76(sup245):S6\u201311.","journal-title":"Scand J Clin Lab Invest"},{"key":"1470_CR15","doi-asserted-by":"crossref","unstructured":"Anonychuk A, Beastall G, Shorter S, Kloss-Wolf R, Neumann P, editors. A framework for assessing the value of laboratory diagnostics. Healthcare Management Forum; 2012. Los Angeles: SAGE Publications Sage CA.","DOI":"10.1016\/j.hcmf.2012.07.015"},{"key":"1470_CR16","doi-asserted-by":"crossref","unstructured":"van Schaik LF, Engelhardt EG, Wilthagen EA, Steeghs N, Coves AF, Joore MA, et al. Factors for a broad technology assessment of comprehensive genomic profiling in advanced cancer, a systematic review. Crit Rev Oncol Hematol. 2024;24(1):104441.","DOI":"10.1016\/j.critrevonc.2024.104441"},{"issue":"4","key":"1470_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40273-023-01241-2","volume":"41","author":"T Snowsill","year":"2023","unstructured":"Snowsill T. Modelling the cost-effectiveness of diagnostic tests. Pharmacoeconomics. 2023;41(4):339\u201351.","journal-title":"Pharmacoeconomics"},{"key":"1470_CR18","doi-asserted-by":"crossref","unstructured":"Kramer A, Rubio\u2010Alarc\u00f3n C, van den Broek D, Vessies DC, Van't Erve I, Meijer GA, et al. A scenario\u2010drafting study to explore potential future implementation pathways of circulating tumor DNA testing in oncology. Mol Oncol. 2024;18(11):2730\u201342.","DOI":"10.1002\/1878-0261.13562"},{"key":"1470_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit E, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:192\u2013237.","journal-title":"Ann Oncol"},{"issue":"5","key":"1470_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101628","volume":"8","author":"P Hofman","year":"2023","unstructured":"Hofman P, Calabrese F, Kern I, Adam J, Alarc\u00e3o A, Alborelli I, et al. Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. ESMO Open. 2023;8(5): 101628.","journal-title":"ESMO Open"},{"key":"1470_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.lungcan.2022.04.001","volume":"167","author":"EM Steeghs","year":"2022","unstructured":"Steeghs EM, Groen HJ, Schuuring E, Aarts MJ, Damhuis RA, Voorham QJ, et al. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice. Lung Cancer. 2022;167:87\u201397.","journal-title":"Lung Cancer"},{"issue":"10","key":"1470_CR22","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","volume":"31","author":"G Argil\u00e9s","year":"2020","unstructured":"Argil\u00e9s G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291\u2013305.","journal-title":"Ann Oncol"},{"issue":"1","key":"1470_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, Arnold D, Normanno N, Ta\u00efeb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2023;34(1):10\u201332.","journal-title":"Ann Oncol"},{"issue":"10","key":"1470_CR24","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40273-023-01292-5","volume":"41","author":"M Fagery","year":"2023","unstructured":"Fagery M, Khorshidi HA, Wong SQ, Vu M, IJzerman M. Health economic evidence and modeling challenges for liquid biopsy assays in cancer management: a systematic literature review. Pharmacoeconomics. 2023;41(10):1229\u201348.","journal-title":"Pharmacoeconomics"},{"key":"1470_CR25","unstructured":"Cell-free circulating tumour DNA blood testing to detect EGFR T790M mutation in people with advanced non-small cell lung cancer: a health technology assessment. Ont Health Technol Assess Ser. 2020;20(5):1\u2013176."},{"issue":"9","key":"1470_CR26","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1093\/annonc\/mdx305","volume":"28","author":"PN Aguiar Jr","year":"2017","unstructured":"Aguiar PN Jr, Perry LA, Penny-Dimri J, Babiker H, Tadokoro H, de Mello RA, Lopes GL Jr. The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. Ann Oncol. 2017;28(9):2256\u201363.","journal-title":"Ann Oncol"},{"key":"1470_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00546","volume":"7","author":"E Arriola","year":"2023","unstructured":"Arriola E, Bernab\u00e9 R, Campelo RG, Biscuola M, Enguita AB, L\u00f3pez-R\u00edos F, et al. Cost-effectiveness of next-generation sequencing versus single-gene testing for the molecular diagnosis of patients with metastatic non-small-cell lung cancer from the perspective of Spanish reference centers. JCO Precis Oncol. 2023;7: e2200546.","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"1470_CR28","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/bjc.2012.60","volume":"106","author":"AJ Atherly","year":"2012","unstructured":"Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer. 2012;106(6):1100\u20136.","journal-title":"Br J Cancer"},{"key":"1470_CR29","doi-asserted-by":"crossref","unstructured":"Cheng MM, Palma JF, Scudder S, Poulios N, Liesenfeld O. The clinical and economic impact of inaccurate EGFR mutation tests in the treatment of metastatic non-small cell lung cancer. J Pers Med. 2017;7(3).","DOI":"10.3390\/jpm7030005"},{"issue":"6","key":"1470_CR30","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/14737167.2022.2078310","volume":"22","author":"E de Alava","year":"2022","unstructured":"de Alava E, Pareja MJ, Carcedo D, Arrabal N, Garc\u00eda JF, Bernab\u00e9-Caro R. Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective. Expert Rev Pharmacoecon Outcomes Res. 2022;22(6):1033\u201342.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"10","key":"1470_CR31","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1200\/JCO.2013.53.1186","volume":"32","author":"S Djalalov","year":"2014","unstructured":"Djalalov S, Beca J, Hoch JS, Krahn M, Tsao MS, Cutz JC, Leighl NB. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(10):1012\u20139.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"1470_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.lungcan.2016.05.024","volume":"107","author":"B Doble","year":"2017","unstructured":"Doble B, John T, Thomas D, Fellowes A, Fox S, Lorgelly P. Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: an early decision analytic model of multiplex targeted sequencing. Lung Cancer. 2017;107:22\u201335.","journal-title":"Lung Cancer"},{"issue":"4","key":"1470_CR33","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s00432-022-04034-w","volume":"149","author":"F Englmeier","year":"2023","unstructured":"Englmeier F, Bleckmann A, Br\u00fcckl W, Griesinger F, Fleitz A, Nagels K. Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach. J Cancer Res Clin Oncol. 2023;149(4):1495\u2013511.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1470_CR34","doi-asserted-by":"publisher","first-page":"175883592211126","DOI":"10.1177\/17588359221112696","volume":"14","author":"DA Ezeife","year":"2022","unstructured":"Ezeife DA, Spackman E, Juergens RA, Laskin JJ, Agulnik JS, Hao D, et al. The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. Ther Adv Med Oncol. 2022;14:17588359221112696.","journal-title":"Ther Adv Med Oncol."},{"key":"1470_CR35","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/PO.20.00540","volume":"5","author":"MJ Harvey","year":"2021","unstructured":"Harvey MJ, Cunningham R, Sawchyn B, Montesion M, Reddy P, McBride A, Chawla AJ. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small-cell lung cancer. JCO Precis Oncol. 2021;5:1611\u201324.","journal-title":"JCO Precis Oncol"},{"key":"1470_CR36","doi-asserted-by":"publisher","first-page":"1119506","DOI":"10.3389\/fmed.2023.1119506","volume":"10","author":"T Hofmarcher","year":"2023","unstructured":"Hofmarcher T, Malmberg C, Lindgren P. A global analysis of the value of precision medicine in oncology\u2014the case of non-small cell lung cancer. Front Med (Lausanne). 2023;10:1119506.","journal-title":"Front Med (Lausanne)."},{"issue":"6","key":"1470_CR37","doi-asserted-by":"publisher","first-page":"e569","DOI":"10.3747\/co.27.5995","volume":"27","author":"KM Johnston","year":"2020","unstructured":"Johnston KM, Sheffield BS, Yip S, Lakzadeh P, Qian C, Nam J. Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact. Curr Oncol. 2020;27(6):e569\u201377.","journal-title":"Curr Oncol"},{"issue":"2","key":"1470_CR38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2217\/pme.13.7","volume":"10","author":"RD Lieberthal","year":"2013","unstructured":"Lieberthal RD, Dudash K, Axelrod R, Goldfarb NI. An economic model to value companion diagnostics in non-small-cell lung cancer. Per Med. 2013;10(2):139\u201347.","journal-title":"Per Med"},{"key":"1470_CR39","doi-asserted-by":"crossref","unstructured":"Loubi\u00e8re S, Drezet A, Beau-Faller M, Moro-Sibilot D, Friard S, Wislez M, et al. Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study. Eur Respir J. 2018;51(3):1701467.","DOI":"10.1183\/13993003.01467-2017"},{"issue":"10","key":"1470_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205827","volume":"13","author":"S Lu","year":"2018","unstructured":"Lu S, Yu Y, Fu S, Ren H. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China. PLoS ONE. 2018;13(10): e0205827.","journal-title":"PLoS ONE"},{"issue":"1","key":"1470_CR41","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1186\/s12885-021-08407-1","volume":"21","author":"E Nadal","year":"2021","unstructured":"Nadal E, Bautista D, Cabez\u00f3n-Guti\u00e9rrez L, Ortega AL, Torres H, Carcedo D, et al. Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario. BMC Cancer. 2021;21(1):689.","journal-title":"BMC Cancer"},{"issue":"1","key":"1470_CR42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.lungcan.2015.07.006","volume":"90","author":"Y Narita","year":"2015","unstructured":"Narita Y, Matsushima Y, Shiroiwa T, Chiba K, Nakanishi Y, Kurokawa T, Urushihara H. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer. Lung Cancer. 2015;90(1):71\u20137.","journal-title":"Lung Cancer"},{"issue":"5","key":"1470_CR43","doi-asserted-by":"publisher","first-page":"e735","DOI":"10.1016\/j.cllc.2018.05.012","volume":"19","author":"D Paolini","year":"2018","unstructured":"Paolini D, Tiseo M, Demma F, Furneri G, Dionisi M, Akkermans M, Marchetti A. Ventana ALK (D5F3) in the detection of patients affected by anaplastic lymphoma kinase-positive non-small-cell lung cancer: clinical and budget effect. Clin Lung Cancer. 2018;19(5):e735\u201343.","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"1470_CR44","doi-asserted-by":"publisher","first-page":"5278","DOI":"10.3390\/curroncol28060441","volume":"28","author":"YP Patel","year":"2021","unstructured":"Patel YP, Husereau D, Leighl NB, Melosky B, Nam J. Health and budget impact of liquid-biopsy-based comprehensive genomic profile (CGP) testing in tissue-limited advanced non-small cell lung cancer (aNSCLC) patients. Curr Oncol. 2021;28(6):5278\u201394.","journal-title":"Curr Oncol"},{"issue":"1","key":"1470_CR45","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12885-022-09397-4","volume":"22","author":"F Rojo","year":"2022","unstructured":"Rojo F, Conde E, Torres H, Cabez\u00f3n-Guti\u00e9rrez L, Bautista D, Ramos I, et al. Clinical and economic impact of \u201cROS1-testing\u201d strategy compared to a \u201cno-ROS1-testing\u201d strategy in advanced NSCLC in Spain. BMC Cancer. 2022;22(1):292.","journal-title":"BMC Cancer"},{"issue":"4","key":"1470_CR46","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/JTO.0000000000000474","volume":"10","author":"D Romanus","year":"2015","unstructured":"Romanus D, Cardarella S, Cutler D, Landrum MB, Lindeman NI, Gazelle GS. Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer. J Thorac Oncol. 2015;10(4):586\u201394.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1470_CR47","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1186\/s12885-020-07240-2","volume":"20","author":"L Schluckebier","year":"2020","unstructured":"Schluckebier L, Caetano R, Garay OU, Montenegro GT, Custodio M, Aran V, Gil FC. Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients. BMC Cancer. 2020;20(1):875.","journal-title":"BMC Cancer"},{"issue":"2","key":"1470_CR48","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/13696998.2018.1549056","volume":"22","author":"J Signorovitch","year":"2019","unstructured":"Signorovitch J, Zhou Z, Ryan J, Anhorn R, Chawla A. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer. J Med Econ. 2019;22(2):140\u201350.","journal-title":"J Med Econ"},{"issue":"12","key":"1470_CR49","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s40273-021-01073-y","volume":"39","author":"M Simons","year":"2021","unstructured":"Simons M, Ret\u00e8l VP, Ramaekers BLT, Butter R, Mankor JM, Paats MS, et al. Early cost effectiveness of whole-genome sequencing as a clinical diagnostic test for patients with inoperable stage IIIB, C\/IV non-squamous non-small-cell lung cancer. Pharmacoeconomics. 2021;39(12):1429\u201342.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1470_CR50","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jval.2022.07.006","volume":"26","author":"M Simons","year":"2023","unstructured":"Simons M, Uyl-de Groot CA, Ret\u00e8l VP, Mankor JM, Ramaekers BLT, Joore MA, van Harten WH. Cost-effectiveness and budget impact of future developments with whole-genome sequencing for patients with lung cancer. Value Health. 2023;26(1):71\u201380.","journal-title":"Value Health."},{"key":"1470_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.19.00002","volume":"3","author":"L Steuten","year":"2019","unstructured":"Steuten L, Goulart B, Meropol NJ, Pritchard D, Ramsey SD. Cost effectiveness of multigene panel sequencing for patients with advanced non-small-cell lung cancer. JCO Clin Cancer Inform. 2019;3:1\u201310.","journal-title":"JCO Clin Cancer Inform."},{"issue":"32","key":"1470_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18620","volume":"18","author":"M Westwood","year":"2014","unstructured":"Westwood M, Joore M, Whiting P, van Asselt T, Ramaekers B, Armstrong N, et al. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2014;18(32):1\u2013166.","journal-title":"Health Technol Assess"},{"key":"1470_CR53","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00201","volume":"6","author":"HB Wolff","year":"2022","unstructured":"Wolff HB, Steeghs EMP, Mfumbilwa ZA, Groen HJM, Adang EM, Willems SM, et al. Cost-effectiveness of parallel versus sequential testing of genetic aberrations for stage IV non-small-cell lung cancer in the Netherlands. JCO Precis Oncol. 2022;6: e2200201.","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"1470_CR54","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jmoldx.2022.04.010","volume":"24","author":"D Zou","year":"2022","unstructured":"Zou D, Ye W, Hess LM, Bhandari NR, Ale-Ali A, Foster J, et al. Diagnostic value and cost-effectiveness of next-generation sequencing-based testing for treatment of patients with advanced\/metastatic non-squamous non-small-cell lung cancer in the United States. J Mol Diagn. 2022;24(8):901\u201314.","journal-title":"J Mol Diagn"},{"issue":"3","key":"1470_CR55","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jval.2021.07.019","volume":"25","author":"F Alarid-Escudero","year":"2022","unstructured":"Alarid-Escudero F, Schrag D, Kuntz KM. CDX2 biomarker testing and adjuvant therapy for stage II colon cancer: an exploratory cost-effectiveness analysis. Value Health. 2022;25(3):409\u201318.","journal-title":"Value Health."},{"issue":"12","key":"1470_CR56","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s40273-014-0207-1","volume":"32","author":"SR Alberts","year":"2014","unstructured":"Alberts SR, Yu TM, Behrens RJ, Renfro LA, Srivastava G, Soori GS, et al. Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer. Pharmacoeconomics. 2014;32(12):1231\u201343.","journal-title":"Pharmacoeconomics"},{"issue":"23","key":"1470_CR57","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.21037\/atm-2022-77","volume":"10","author":"VS Chaudhari","year":"2022","unstructured":"Chaudhari VS, Issa AM. Cost-effectiveness of precision molecular diagnostic tests for stage II colorectal cancer. Ann Transl Med. 2022;10(23):1260.","journal-title":"Ann Transl Med."},{"issue":"9","key":"1470_CR58","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1158\/1055-9965.EPI-21-0078","volume":"30","author":"G Jongeneel","year":"2021","unstructured":"Jongeneel G, Greuter MJE, Kunst N, van Erning FN, Koopman M, Medema JP, et al. Early cost-effectiveness analysis of risk-based selection strategies for adjuvant treatment in stage II colon cancer: the potential value of prognostic molecular markers. Cancer Epidemiol Biomarkers Prev. 2021;30(9):1726\u201334.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1470_CR59","doi-asserted-by":"publisher","first-page":"175628482199571","DOI":"10.1177\/1756284821995715","volume":"14","author":"G Jongeneel","year":"2021","unstructured":"Jongeneel G, Greuter MJE, van Erning FN, Koopman M, Vink GR, Punt CJA, Coup\u00e9 VMH. Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients. Therap Adv Gastroenterol. 2021;14:1756284821995715.","journal-title":"Therap Adv Gastroenterol."},{"issue":"8","key":"1470_CR60","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s40273-021-01047-0","volume":"39","author":"YH To","year":"2021","unstructured":"To YH, Degeling K, Kosmider S, Wong R, Lee M, Dunn C, et al. Circulating tumour DNA as a potential cost-effective biomarker to reduce adjuvant chemotherapy overtreatment in stage II colorectal cancer. Pharmacoeconomics. 2021;39(8):953\u201364.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1470_CR61","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00268-004-7256-0","volume":"28","author":"F Borie","year":"2004","unstructured":"Borie F, Combescure C, Daur\u00e8s JP, Tr\u00e9tarre B, Millat B. Cost-effectiveness of two follow-up strategies for curative resection of colorectal cancer: comparative study using a Markov model. World J Surg. 2004;28(6):563\u20139.","journal-title":"World J Surg"},{"issue":"5","key":"1470_CR62","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.gassur.2004.02.012","volume":"8","author":"F Borie","year":"2004","unstructured":"Borie F, Daur\u00e8s JP, Millat B, Tr\u00e9tarre B. Cost and effectiveness of follow-up examinations in patients with colorectal cancer resected for cure in a French population-based study. J Gastrointest Surg. 2004;8(5):552\u20138.","journal-title":"J Gastrointest Surg"},{"issue":"4","key":"1470_CR63","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/01.SLA.0000059989.55280.33","volume":"237","author":"GS Gazelle","year":"2003","unstructured":"Gazelle GS, Hunink MG, Kuntz KM, McMahon PM, Halpern EF, Beinfeld M, et al. Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis. Ann Surg. 2003;237(4):544\u201355.","journal-title":"Ann Surg"},{"issue":"11","key":"1470_CR64","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/1097-0142(19900601)65:11<2580::AID-CNCR2820651131>3.0.CO;2-I","volume":"65","author":"J Kievit","year":"1990","unstructured":"Kievit J, van de Velde CJ. Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation. A Markov analysis. Cancer. 1990;65(11):2580\u20137.","journal-title":"Cancer"},{"issue":"11","key":"1470_CR65","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1023\/A:1008265614183","volume":"8","author":"J Norum","year":"1997","unstructured":"Norum J, Olsen JA. A cost-effectiveness approach to the Norwegian follow-up programme in colorectal cancer. Ann Oncol. 1997;8(11):1081\u20137.","journal-title":"Ann Oncol"},{"key":"1470_CR66","doi-asserted-by":"crossref","unstructured":"Wanis KN, Maleyeff L, Van Koughnett JAM, P HDC, Ott M, Leslie K, et al. Health and economic impact of intensive surveillance for distant recurrence after curative treatment of colon cancer: a mathematical modeling study. Dis Colon Rectum. 2019;62(7):872\u201381.","DOI":"10.1097\/DCR.0000000000001364"},{"issue":"2","key":"1470_CR67","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2023.11.009","volume":"35","author":"T Henriksen","year":"2024","unstructured":"Henriksen T, Demuth C, Frydendahl A, Nors J, Nesic M, Rasmussen M, et al. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer\u2014evaluation in a nationwide Danish cohort. Ann Oncol. 2024;35(2):229\u201339.","journal-title":"Ann Oncol"},{"issue":"1","key":"1470_CR68","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023;29(1):127\u201334.","journal-title":"Nat Med"},{"key":"1470_CR69","doi-asserted-by":"crossref","unstructured":"Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. New Engl J Med. 2022;386(24):2261\u201372.","DOI":"10.1056\/NEJMoa2200075"},{"issue":"5","key":"1470_CR70","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1158\/1078-0432.CCR-22-2538","volume":"29","author":"I van\u2019t Erve","year":"2023","unstructured":"van\u2019t Erve I, Medina JE, Leal A, Papp E, Phallen J, Adleff V, et al. Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells. Clin Cancer Res. 2023;29(5):899\u2013909.","journal-title":"Clin Cancer Res"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01470-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01470-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01470-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T06:02:21Z","timestamp":1745215341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01470-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1470"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01470-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,8]]},"assertion":[{"value":"19 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The COIN project is funded by the ZonMw ' Personalised Medicine' programme (project number 848101011), PGDX and CZ and this research was funded by the CAN.HEAL project through the European Commission EU4Health Program 2021\u20132027 under Grant No. 101080009.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A.K., L.F.S., D.B., I.G.I., L.G.C., W.H.H., V.M.H.C., and V.P.R. declare no conflict of interest. R.J.A.F reports public private partnership consortia grants in collaboration with Labcorp (Personal Genome Diagnostics), Delfi Diagnostics, Solvias (Cergentis BV), MERCK BV, outside the submitted work. In addition, R.J.A.F. has several patents pending\n                      .\n                      E.S. reports lectures for Bio-Rad, Seracare, Roche, Biocartis, Illumina, Lilly, Janssen Cilag (Johnson&Johnson), AstraZeneca and Agena Bioscience; he is consultant in advisory boards for MSD\/Merck, GSK, AstraZeneca, Astellas Pharma, Sysmex, Roche, Novartis, Bayer, BMS, Lilly, Amgen, Illumina, Agena Bioscience, Janssen Cilag (Johnson&Johnson), Sinnovisionlab, Diaceutics, CC Diagnostics; and received research grants from Biocartis, Invitae-ArcherDX, AstraZeneca, Agena Bio-science, BMS, Bio-Rad, Roche, Boehringer Ingelheim, CC Diagnostics, SNN\/EFRO and Abbott (all paid to UMCG account); and travel reimbursements from Bio-Rad, Abbott, Illumina, Agena Bioscience, Roche, IQNPath and BioRAD. M.J.L.L. has had advisory roles (institutional) with AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Illumina, Janssen, Lilly, Merck Sharp & Dohme and Roche. G.A.M. is co-founder and board member (CSO) of CRCbioscreen BV, CSO of Health-RI (Dutch National Health Data infrastructure for research & innovation), and member of the supervisory board of IKNL (Netherlands Comprehensive Cancer Organisation). He has a research collaboration with CZ Health Insurances (cash matching to ZonMw grant) and he has research collaborations with Exact Sciences, Sysmex, Sentinel Ch. SpA, Personal Genome Diagnostics (PGDX), DELFi and Hartwig Medical Foundation; these companies provide materials, equipment and\/or sample\/genomic analyses.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"According to the Dutch Law on Medical Scientific Research (WMO), this study did not require approval by a medical ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All invited experts that participated in the expert roundtable consented before participating.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Extracted literature findings are available in Online Resource 4 in the ESM. Transcripts of the expert roundtable will not be shared to ensure anonymity of the participants.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"AK, VC and VR developed the ideas and the methods for this study. AK and LS conducted the screening, the data extraction and the data analysis of the literature. AK, LS, VC, VR, and WH developed the first version of the recommendations. These recommendations were revised by all authors, after which AK and LS drafted the first version of the manuscript. The manuscript was reviewed in multiple rounds by all authors.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}